Robotic therapy, rapid exchange FFR and automated contrast delivery provide advanced workflow solutions at Minnesota Hospital
WALTHAM, MA - August 11, 2016 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, and ACIST Medical Systems, Inc., a Bracco Group company, pioneer and global market leader of advanced imaging modalities for cardiology, are providing three leading edge technologies that improve workflow.
"I am excited to work with both companies to bring innovative solutions to the cath lab that enhance patient care," said Gregory Helmer, MD, FACC. "Rapid FFR and Robotic PCI are significant contributions to PCI procedures and may improve safety, lesion assessment, and bring further precision to our interventional procedures."
The CorPath® System is the first FDA-cleared robotic-assisted system for percutaneous coronary intervention, offering robotic precision that may improve clinical outcomes and protection for physicians and staff from serious occupational hazards in the cath lab. The ACIST RXi technology provides the reassurance of accurate and reliable FFR measurements and the advantages of Rapid Exchange technology. ACIST CVi simplifies contrast injection for procedures while enhancing safety, efficiency, control and image quality.
"Both Corindus and ACIST share the strong vision of how physicians and their teams should operate in the cath lab,” said Mark Toland, Chief Executive Officer, Corindus Vascular Robotics. “This collaboration is the first step towards realizing this vision by providing innovative solutions to optimize workflow, improve safety, and eventually enhance patient care.”
“We look forward to furthering the reach of Corindus and ACIST so that more clinicians and patients can benefit from these advanced technologies,” said Tom Morizio, President & COO, ACIST Medical Systems, Inc. “The ultimate goal of this collaboration is to advance the science of interventional cardiology to provide the best care possible for patients.”
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: